Go to the list of all blogs
published in Blogs
Sep 08, 2026
Core Scientific (CORZ) Stock Slides -12.9% Over 30 Days During AI Infrastructure Shift

Core Scientific (CORZ) Stock Slides -12.9% Over 30 Days During AI Infrastructure Shift

Key Takeaways

  • Core Scientific shares fell roughly 12.9% over the past 30 days, declining from a closing price near $21 to about $18.31.
  • The drop extends a steeper three-month slide of approximately 33%, as investors repriced the company's capital-intensive AI infrastructure transition.
  • Second-quarter results featured a net loss of about $1.16 billion, driven primarily by non-cash changes in the fair value of warrants.
  • Investor sentiment remains divided between the company's multi-billion-dollar colocation contracts and persistent losses, heavy spending, and customer concentration with CoreWeave.
  • Watch items include new colocation customer signings, execution on the CoreWeave and AMD agreements, and the continued wind-down of bitcoin mining.

Company Background and Current Positioning

Core Scientific, Inc. operates as a digital infrastructure provider based in Austin, Texas. The firm focuses on designing and running large-scale data centers optimized for high-density colocation services, with a growing emphasis on supporting artificial intelligence workloads. It continues to generate some revenue from digital asset self-mining and hosting, though management has been steadily reducing bitcoin mining operations to prioritize the more predictable colocation segment.

After emerging from Chapter 11 bankruptcy in early 2024, the company has repositioned toward AI data center operations. Its key relationship is a 12-year agreement with CoreWeave that covers around 590 megawatts across several sites and carries roughly $10.2 billion in contracted revenue. Many investors track the stock as an indicator of how former bitcoin miners are adapting to AI and high-performance computing demands.

Stock Performance Over the Past Month and Quarter

In the last 30 days, CORZ dropped about 12.9%, moving from a close near $21.01 down to roughly $18.31. The path was uneven, with shares easing from the low-$20s early in August to an intraday low around $16 late in the month before a modest rebound.

The three-month view shows a sharper decline of approximately 33%, with the stock retreating from levels near $27 in early June. This longer slide points to a sustained market reassessment of the economics behind the AI infrastructure push rather than a one-off reaction.

Drivers Behind the Recent 30-Day Move

The pullback stemmed from a mix of results and sentiment rather than any single catalyst. Late in July the company posted second-quarter revenue of about $164.2 million and a net loss near $1.16 billion. Management attributed most of the loss to non-cash fair-value adjustments on warrants tied to the stock’s earlier appreciation. Still, the headline figure added to concerns about ongoing profitability.

Additional pressure came from elevated capital spending of roughly $797.5 million in the quarter and heavy reliance on a concentrated customer. CoreWeave represents the bulk of colocation revenue, raising questions about execution and counterparty risk. A new partnership with AMD that could involve up to 2.5 gigawatts of AI capacity and related warrants offered longer-term potential but also highlighted possible dilution effects that weighed on near-term views.

Broader sector volatility in bitcoin mining and AI infrastructure names played a role as well, with traders shifting away from high-beta, capital-heavy stocks. The ongoing reduction in bitcoin mining removed a near-term cash-flow source while investors focused on losses and dilution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Performance Factors Over the Past Quarter

The three-month decline reflects a wider reevaluation of the transition costs. Colocation revenue grew to represent about 83% of second-quarter totals, up markedly from a year earlier, and the company raised its cash gross-profit target for the CoreWeave deal to 80%–85%. It also completed a $3.3 billion senior secured notes offering at 7.75% to support development.

These positives were offset by sizable net losses, non-cash impairment charges on mining assets, and the high capital needs of scaling gigawatt-level capacity. The company exited a chip-supply agreement with Block’s Proto subsidiary for about $41.9 million as part of the mining wind-down. With free cash flow still negative and the AI colocation ramp not yet complete, the market has adjusted the valuation downward despite the expanding backlog of contracted business.

Key Items to Monitor Ahead

Future performance will hinge on several factors. New colocation contracts beyond CoreWeave will be important for reducing customer concentration. Progress on the CoreWeave and AMD deals, measured by energized megawatts and service-ready dates, will also draw attention. Quarterly updates will be reviewed for movement toward positive adjusted EBITDA and any further non-cash warrant volatility.

Broader conditions such as interest rates and financing access remain relevant given the company’s debt load and expansion plans. Sector sentiment involving peers like IREN and NVDA may continue to influence trading. These elements deserve careful consideration beyond short-term price action.

Using AI Tools for Deeper Market Context

When evaluating names like CORZ, I often review Tickeron’s Trending AI Robots to see how top-performing automated strategies are positioned across the digital infrastructure space. The page highlights bots with strong recent signals, helping put algorithmic activity around the stock and its peers into perspective without replacing fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CORZ

CORZ in +1.53% Uptrend, advancing for three consecutive days on October 05, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CORZ advanced for three days, in 225 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CORZ's RSI Oscillator exited the oversold zone, 21 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CORZ as a result. In 48 of 57 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for CORZ turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 30 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

The 50-day moving average for CORZ moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for CORZ entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.385) is normal, around the industry mean (18.522). P/E Ratio (74.103) is within average values for comparable stocks, (158.311). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (104.490).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. CORZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CORZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Twilio (NYSE:TWLO), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), Okta (NASDAQ:OKTA), Zscaler (NASDAQ:ZS), MongoDB (NASDAQ:MDB).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.56B. The market cap for tickers in the group ranges from 48.8K to 3.78T. MSFT holds the highest valuation in this group at 3.78T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 26%. BIRD experienced the highest price growth at 46%, while VERI experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 70
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
CORZ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ComputerCommunications

Industry
N/A
Address
838 Walker Road
Phone
+1 512 402-5233
Employees
325
Web
https://www.corescientific.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
Core Scientific (CORZ) Stock Slides -12.9% Over 30 Days During AI Infrastructure Shift